ERBB2 and breast cancer: Another study evaluating the addition of palbociclib to endocrine therapy was RENATA, a prospective study which included 128 Argentine women with breast cancer, positive hormone receptors, and HER-2 negative, 20% of which were premenopausal, while 44% had visceral metastasis.